Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: AZT, ddI, or ddC (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). Prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). Patients must have: Documented HIV infection or diagnosis of AIDS. Life expectancy of at least 3 months. Prior Medication: Allowed: Prior AZT, ddI, or ddC. Prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Active, serious infections (other than HIV infections) that require parenteral antibiotic therapy. Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. Gastrointestinal malabsorption syndrome or inability to receive oral medication. Concurrent Medication: Excluded: Diuretics. Amphotericin B. Aminoglycoside antibiotics. Parenteral antibiotics. Other nephrotoxic agents. Other investigational agents. Non-steroidal anti-inflammatory drugs. Aspirin. Prior Medication: Excluded within 2 weeks prior to study entry: Diuretics. Amphotericin B. Aminoglycoside antibiotics. Parenteral antibiotics. Other nephrotoxic agents. Other investigational agents. Excluded within 3 days prior to study entry: Non-steroidal anti-inflammatory drugs. Aspirin. Active substance abuse (including alcohol or drug abuse).